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Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)-γ agonists commonly used as insulin-
sensitizing drugs for the treatment of type 2 diabetes. In the last decade, PPAR-γ agonists have received increasing attention for
their neuroprotective properties displayed in a variety of neurodegenerative diseases, including Parkinson’s disease (PD), likely
related to the anti-infammatoryactivity of these compounds. Recent studies indicate that neuroinﬂammation,speciﬁcally reactive
microglia, plays important roles in PD pathogenesis. Moreover, after the discovery of inﬁltrating activated Limphocytes in the
substantia nigra (SN) of PD patients, most recent research supports a role of immune-mediated mechanisms in the pathological
process leading to chronic neuroinﬂammation and dopaminergic degeneration. PPAR-γ are highly expressed in cells of both
central and peripheral immune systems, playing a pivotal role in microglial activation as well as in monocytes and T cells
diﬀerentiation,in which they act as keyregulators ofimmuneresponses. Here, we review preclinical evidences ofPPAR-γ-induced
neuroprotection in experimental PD models and highlight relative anti-inﬂammatory mechanisms involving either central or
peripheral immunomodulatoryactivity. Speciﬁc targeting ofimmunefunctionscontributingto neuroinﬂammationeitherdirectly
(central) or indirectly (peripheral) may represent a novel therapeutic approach for disease modifying therapies in PD.
1.Introduction
Thiazolidinediones (TZDs), includingrosiglitazone and pio-
glitazone, are currently in clinical use as insulin-sensitizing
agents for the treatment of type 2 diabetes [1]. These drugs
were originally designedasagonistsoftheperoxisome prolif-
erator-activated receptor-γ (PPAR-γ), belonging to the hor-
monenuclearreceptorsuperfamily.PPAR-γ mediatesligand-
dependent transcription and is activated, beside synthetic
agonists TZD, by naturally occurring compounds, such as
longchain fatty acids and the prostaglandin 15-deoxy Δ,
prostaglandin J2 (15d-PGJ2), but also few nonsteroidal anti-
inﬂammatory drugs (NSAIDs), as ibuprofen, fenoprofen,
and indomethacin [2–6]. In the last decade, the neuropro-
tective properties of PPAR-γ agonists have received increas-
ing attention and researchers have provided a multitude
of evidences in preclinical models of a variety of acute
and chronic neurodegenerative conditions, including PD,
Alzheimer’s disease, cerebral ischemia, amyotrophic lateral
sclerosis, and spinal cord injury. These evidences have led to
rosiglitazone evaluation in phase II and III clinical trials in
patients with Alzheimer’s disease and ischemia [7–15].
2.SafetyConcernsofTZDs Therapy
TZDs include troglitazone, which was removed from the
market because of hepatotoxicity, and two currently avail-
able agents, rosiglitazone (Avandia, GlaxoSmithKline) and
pioglitazone (Actos, Takeda). Rosiglitazone was introduced
into the market in 1999 and has been widely used as
monotherapy or in ﬁxed-dose combinations with either
metformin (Avandamet, GlaxoSmithKline) or glimepiride
(Avandaryl, GlaxoSmithKline).
TZDs safety has been constantly monitored, mostly for
the cardiovascular risks in diabetic patients, since more than
65% of deaths in patients with diabetes are from cardio-
vascular causes [16]. Multicentre studies aimed at assessing
rosiglitazone-associated risks for cardiovascular diseases in
diabetes have been recently completed [17–21]. The most
reliable and informative studies are the ADOPT [19],2 Parkinson’s Disease
DREAM [21] and the recently completed RECORD studies
for rosiglitazone [18], and the PROactive study for piogli-
tazone [22]. Few meta-analysis have also investigated the
cardiovascular risks of TZDs in diabetes, leading however, to
controversial conclusion [16, 23, 24]. Both rosiglitazone and
pioglitazone have been associated dose-dependently with
ﬂuid retention and accumulation, increased body weight,
and increased LDL cholesterol concentration, that may
indirectly lead to heart failure in diabetic patients [18, 19,
25]. On the other hand, there is no evidence of TZDs
direct cardiotoxicity. Moreover, TZDs have been shown to
improve some cardiovascular risk markers associated with
diabetes, as insulin sensitivity, blood pressure, and coagu-
lation factors [26, 27]. Beside cardiovascular complications,
in diabetic patients rosiglitazone has been associated with
an increased risk of bone fractures, particularly in woman
[18].
Given the intrinsic risk of cardiovascular complications
in diabetic patients, concerns on TZDs safety have recently
led to rosiglitazone withdrawal from the market in Europe
and its inclusion in a restricted access program in the US as
hypoglycemic drug (FDA safety Information). (http://www
.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafe-
tyInformationforPatientsandProviders/UCM226959.pdf).
In contrast, no data are available up to date for non-
diabetic or PD patients. It should be also noticed that
rosiglitazone is currently in phase III clinical trial on
Alzheimer disease, as well as several other diseases,
including ischemia, cancer, and asthma (NCT00348140,
NCT00265148, NCT00405015, NCT00369174, and
NCT00119496). Overall, available data on TZDs safety,
while not voiding studies for use of these drugs in other
chronic diseases as PD, prompt for search of new PPAR-γ
agonists with increased CNS permeability, which would
likely permit to use lower doses regimens thus reducing
peripheral side-eﬀects risks.
3.CellularDistributionofPPAR-Gamma
PPAR-γ has been demonstrated in a large variety of cells.
The highest level of expression is shown by adipose tissue
and by cells of the peripheral and central immune systems
[6, 28–32]. This distribution pattern reﬂects the actions
of PPAR-γ in regulating glucose and lipid metabolism,
in promoting lipid storage and adipocyte diﬀerentiation
[6, 33, 34]. Moreover, peripheral PPAR-γ is involved in
the modulation of inﬂammatory cytokines production by
monocyte/macrophages and endothelial cells, as well as in
immune cell diﬀerentiation and function [3, 35]. In the
centralnervoussystem(CNS),PPAR-γ isexpressed inseveral
celltypesincludingmicroglia,neurons,astrocytes,andoligo-
dendrocytes[2,36,37].Microglialcellsconstitutivelyexpress
PPAR-γ, its levels being tightly regulated and dependent
on microglial functional state [38]. In neurons, PPAR-
γ immunoreactivity appears mainly as a nuclear labeling
although sometimes cytoplasmic staining is detectable in
some cortical neuron [37, 39]. High levels of PPAR-γ have
been found in the piriform cortex and olfactory tubercle, in
the basal ganglia, in rhomboid, centromedial, and parafas-
cicular thalamic nuclei, in the reticular formation, and in
the stellate cells of cerebellar cortex [37]. The abundance
of PPAR-γ in basal ganglia regions, and areas expressing
dopamine receptors supports the increasing interest for
PPAR-γ agonists in PD management. PPAR-γ expression in
astrocytesresultsinsomewayinhomogeneous,sinceinwhite
matter structures PPAR-γ positive and negative astrocytes
were found within the same area, albeit they have been
found homogeneously expressed in adult cultured cortical
astrocytes [36, 37].
4.PPAR-GammaAgonistsinPreclinical
Models of PD
PD is a neurodegenerative disorder characterized by the
progressive death of dopaminergic neurons of the substan-
tia nigra pars compacta (SNc), resulting in a progressive
deﬁciency of nigrostriatal dopamine transmission. Clinical
symptoms of PD generally manifest when striatal dopamine
(DA) levels are largely reduced and most nigral neurons are
lost. The pathological development underlying neurodegen-
eration, at the time the diagnosis is made, is characterized
by an unbalanced neuronal network due to a complex
scenario of malfunctioning cellular components, including
oxidative stress, impaired protein disposal systems, and
chronic neuroinﬂammation [40].
Animal models of PD have been fruitfully used for
contributing to a better knowledge of major mechanisms
involved in this disease and to explore new potential
therapies. Animal models of PD should possess the highest
number of features of human PD (face validity), underlying
neuropathology should evolve as much as possible as PD
and should respond to treatments in a manner comparable
to human PD (predictive validity). Lastly, they should also
reproduce the complex scenario of multiple interaction
between neuronal elements and surrounding cells (construct
validity). Among cells that play a relevant role in this
scenario, microglia, astrocytes, and endothelial cells are
major players.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
administration has been widely used in animals to reproduce
PD symptoms, and, among animals, primates and mice have
been used, the latter being easy to handle and aﬀordable.
Among the diﬀerent MPTP-based models used so far, the
acute MPTP, the subacute MPTP and the chronic MPTP
paradigms have provided compelling results for a role of
PPAR-γ inneuroinﬂammationandneurodegenerationinPD
[8, 9, 41]. In this section, evidences for PPAR-γ-mediated
n e u r o p r o t e c t i o ni nd i ﬀerent MPTP-based PD models are
summarized.
4.1.AcuteMPTP. TheacuteMPTP model,consistingofmale
C57BL/6 mice that received four intraperitoneal adminis-
tration of MPTP-HCl (15mg/kg) at 2-h intervals in one
day has been used by Breidert and colleagues [8]. This
treatment determined a signiﬁcant reduction of tyrosine
hydroxylase (TH)-positive cells in the SNc at 2, 5, and 8 daysParkinson’s Disease 3
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.4 Parkinson’s Disease
after the last neurotoxin injection (Table 1). 20mg/kg/day
of pioglitazone, administered in rodent chows, prevented
the dopaminergic cell loss in the SNc and attenuated the
MPTP-induced glial activation. Furthermore, whereas TH
immunoreactivity in the striatum was decreased in MPTP-
treated mice as compared to controls, pioglitazone treatment
did not signiﬁcantly prevent striatal TH immunoreactivity
loss, suggesting that the neuroprotective mechanism of this
drug at dopamine cell-body level was somehow selective
(Table 1). However, MPTP-induced decline of striatal tis-
sue content of DA, DOPAC, and HVA was partially but
signiﬁcantly prevented by pioglitazone (Table 1). Overall,
although the authors hypothesized that a higher energy
demand of striatal nerve terminals could make the striatum
more vulnerable to MPTP toxicity, masking the ability of
pioglitazone to show a protective eﬀect, it remains to be
investigated why dopamine terminals were less protected
than dopamine cell bodies.
4.2. Subacute MPTP. Dehmer and colleagues used the
subacute MPTP model in C57BL/6 mice, consisting of
30mg/kg i.p. MPTP at 24h intervals for 2 or 5 days
[9]. 20mg/kg/day pioglitazone was administered in rodent
chows, starting 4 days before MPTP injection. Animal were
killed one week after the last MPTP administration. By
using this protocol, the authors showed that subacute MPTP
administration caused 50% loss of TH positive neurons in
the SNc, whereas pioglitazone administration completely
protected the SNc from cell loss. In addition, pioglitazone
treatment partially prevented MPTP-induced striatal DA
decline, whereas reduction of DOPAC and HVA were not
aﬀected (Table 1).
4.3. Chronic MPTP. In the study by Schintu and col-
leagues, the authors used the chronic MPTP plus probenecid
(MPTPp) mouse model of progressive PD to assess the ther-
apeutic eﬃcacy of rosiglitazone on neurodegeneration, neu-
roinﬂammation and behavioural impairment [15]. In this
study C57Bl/6J mice received 10 doses of MPTP (25mg/kg
i.p.) and probenecid (250mg/kg i.p.) administered twice a
week for 5 weeks. Rosiglitazone (10mg/kg i.p.) was admin-
istered daily until sacriﬁce, three days after last neurotoxin
administration. The eﬃcacy of rosiglitazone in preventing
the deleterious eﬀect of chronic MPTPp was assessed in a
wide variety of behavioural and biochemical tests. In partic-
ular, mice chronically treated with MPTPp displayed typical
features of PD, including progressive impairment of motor
and olfactory functions (Figure 1) associated with partial
loss of TH-positive neurons in the SNc (Table 1), decrease
of DA and DOPAC content and dynorphin mRNA levels in
the striatum, and intense microglial and astroglial response
in the SNc and striatum. Chronic rosiglitazone administered
in association with MPTPp, completely prevented motor
and olfactory dysfunctions and loss of TH-positive cells in
the SNc (Figure 1 and Table 1). In the striatum, MPTPp-
induced loss of striatal dopamine was partially prevented
by rosiglitazone, whereas decrease in DOPAC content and
dynorphin were fully counteracted. Therefore, these results
clearly showed that DA neurons preservation by the PPAR-
γ agonist was associated with preservation of motor func-
tions. Moreover, while emphasizing the sensibility of striatal
DA terminals to MPTPp chronic treatment, this study
interrelated rosiglitazone-mediated preservation of motor
functions to level of DA damage in the striatum, somehow
reproducing a crucial feature of PD, where the appearance
of behavioural deﬁcits is strictly correlated with a threshold
damage of striatal DA transmission.
4.4. Intrastriatal LPS. Hunter and coworkers tested the
neuroprotective potential of the anti-inﬂammatory drug
celecoxib, an inhibitor of cyclo-oxygenase-2 (COX-2) and
the PPAR-γ agonist pioglitazone against the neuronal dam-
age induced by intrastriatal injection of lipopolysaccharide
(LPS) in rats [42]. Celecoxib (administered twice a day at
10mg/kg, for four days before LPS injection) and piogli-
tazone (20mg/kg daily for four days before LPS injection)
prevented the loss of dopaminergic neurons and striatal DA
decline, as observed 3 day after LPS injection. In addition,
Celecoxib and pioglitazone decreased the neuroinﬂamma-
toryreactionandrestoredmitochondrialfunction,providing
a mechanism of neuroprotection [43].
5.PPAR-γ Agonistsand Central
InﬂammationinPD
5.1. Microglia. Recent studies indicate that neuroinﬂamma-
tion and microglia activation play important roles in PD
pathogenesis, as suggested by the high levels of reactive
microgliafoundintheSNcofPDpatients[44–46].Microglia
are the resident immune-competent cells of the CNS,
commonly described as the CNS equivalent of macrophages,
havinga rolein monitoringthebrainforimmuneinsultsand
invading pathogens [47–51]. It has been recently reported
thatprimitivemyeloid precursorsgiverise, beforeembryonic
day 8, to microglia residing in the adult CNS in the steady
state [52]. Recent interpretation of this cell population
suggests that microglia do not constitute a uniform cell
population but rather comprise a family of cells with
diﬀerentphenotypes,someofwhicharebeneﬁcialandothers
detrimental and toxic for the CNS [53]. In the healthy
brain, the majority of microglia are in the resting state, with
rod-shaped soma ramiﬁed and tiny processes. In this state,
microglia show low expression of molecules associated with
macrophage functions [53]. Upon activating stimuli from
extracellular environment, as damaged neurons, endotoxins,
cytokines, and aberrant proteins, microglia become reac-
tive, progressively switching to diﬀerent stages of activity,
characterized by morphological and phenotypic changes.
Assumption ofmacrophage functions allow themto respond
to pathological insults [45, 49, 54, 55]. Morphologically, at
least three activity stages have been described for reactive
microglia: (i) activated ramiﬁed microglia with elongated
soma, long ticker processes, (ii) ameboid microglia with
round-shaped soma and short tick processes, (iii) phagocitic
microglia with round-shaped soma and vacuolated cyto-
plasm, void of processes [49, 54]. Moreover, microglia canParkinson’s Disease 5
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Figure 1: PPAR-γ agonist rosiglitazone prevents the development of behavioural deﬁcits, as olfactory dysfunction and motor impairment,
in a chronic model of progressive PD [15].
assume diﬀerentstates of eﬀectorfunctions, likely in relation
with the activating stimulus and disease state [55]. Depend-
ing on the environment and level of threat for the SNC,
microglia can temporarily assume a ctotoxic phenotype with
phagocytic functions that is associated with production of
pro-inﬂammatory cytokines as TNF-α, interleukin (IL) -1β,
IL-2, IL-6, and nitric oxide (NO). Alternatively, microglia
can act as antigen-presenting cells, expressing the major
histocompatibility complex (MCH) class II, being therefore
able to interact with adaptive immunity cells (T cells).
In turn, T cells can stimulate microglia to assume either
a cytotoxic phenotype or a phenotype with functions of
neuroprotection and cell renewal through the upregulation
of beneﬁcial factors as insulin-like growth factor (IGF)-
1 and anti-inﬂammatory cytokines and downregulation of
neurodegenerative compounds, as TNF-α [56, 57].
5.2. Reactive Gliosis in PD: Human. In PD, postmortem
studies have reported presence of activated microglia
agglomerates around degenerating dopaminergic neurons
and extracellular melanin in the SNc [46]. Moreover, pro-
inﬂammatory cytokines, as TNF-α,I L - 1 β, IL-2, and IL-6
have been found in high levels in parkinsonian brains as well
as in the serum and cerebrospinal ﬂuid of PD patients [44,
58–62]. Accordingly, increased levels and nuclear translo-
cation of nuclear factor (NF)-kB, a transcription factor
controlling cytokines expression, were also observed in the
SNc of PD patients [63, 64]. Interestingly, in PD gliosis
seems to be limited to microglial activation. Indeed, most
reports did not ﬁnd reactive astrocytosis in the SN of PD
patients, suggesting that the inﬂammatory process in PD is a
unique phenomenon diverse from other neurodegenerative
disorders (Mirza et al. [65]).
5.3. Reactive Gliosis in PD: Experimental PD. Studies in ani-
mal models of PD support the involvement of neuroinﬂam-
mation and pro-inﬂammatory cytokines in dopaminergic
neurodegeneration. MPTP and 6-OHDA-induced neurotox-
icity in rodents are associated with an intense microglial
reaction and with elevated levels of pro-inﬂammatory
cytokines in the SNc [41, 66–72]. Moreover, in the LPS
inﬂammatory model of neurodegeneration, systemic LPS
induces intense neuroinﬂammation and increased levels of
pro-inﬂammatory cytokines in the mouse brain, followed
by dopaminergic degeneration in the SNc [73]. Accordingly,
an atypical production of pro-inﬂammatory cytokines has
been described in a 6-OHDA model of PD, where microglial
activation was associated with a selective subset of cytokines
increase [67]. Remarkably, 6-OHDA-induced dopaminergic
neurodegenerationis exacerbated by the overexpression, and
decreased by inhibition, of the pro-inﬂammatory cytokine
IL-1β, whereas chronic TNF-α expression elicits nigral
degeneration, which demonstrate a direct involvement of
toxic cytokines in DA neurons degeneration [54, 74].
Although most reports of reactive microglia in the PD
brain were derivedfrom observations of terminal stage cases,
leaving unknown if reactive gliosis is a cause or consequence
of the disease, ﬁndings from animal models of PD suggest
that microglia is chronically activated in a neurotoxic phe-
notype [44]( F i g u r e2). Products of degenerating neurons in
PD, as aggregated α-synuclein, ATP, and neuromelanin, may
act as self-antigen to activate microglia in order to induce
a defensive reaction [47, 75–78]. However, in PD, activated
microglia is engaged in a vicious cycle of inﬂammation,
where products from dying neurons and inﬂammatory
compounds chronically released by the microglia itself may
sustain a condition called reactive microgliosis, in which
neuroinﬂammation propagates and ampliﬁes to destroy6 Parkinson’s Disease
Reactive
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Figure 2: PPAR-γ agonists might achieve neuroprotection in PD by anti-inﬂammatory activity targeting cells of the central and
peripheral immune systems. Products from dying neurons as α-synuclein (α-syn), ATP, and neuromelanin activate microglia to assume
a proinﬂammatory phenotype that will be involved in clearing the environment from dangerous agents through the release of factors
such as cytokines endowed with inﬂammatory and recruitment properties. In PD, microglia might have lost the ability to self-modulate,
chronically maintaining a pro-inﬂammatory phenotype (red microglia) and failing to assume an anti-inﬂammatory and neuroprotective
function(green microglia).Activated microgliabecomes,therefore, engaged inaviciouscyclecalledreactive microgliosis,inwhichsustained
neuroinﬂammation contributes to neuronal damage. PPAR-γ, through the speciﬁc inhibition of pro-inﬂammatory cytokines production
and a stimulatory eﬀect on anti-inﬂammatory cytokines, may suppress the microglia activation toward a pro-inﬂammatory/neurotoxic
phenotypes, while directing it toward a neuroprotective phenotype (see text for references). In addition, in PD peripheral T lymphocytes
activation is altered in that pro-inﬂammatory phenotypes (violet) exceed anti-inﬂammatory ones (green). Abnormally activated T cells
inﬁltrateintothe CNS,reachingthe damagedSNc.Herein,theymaydrive microgliato acquire theneurotoxic phenotypeto thedetriment of
less toxic orneuroprotective states, actively contributing to the pathological processes. Peripheral PPAR-γ candirect lymphocytes activation,
selectively suppressing subsets of activated T cells which sustain tissue inﬂammation. Counteracting the disease-dysregulated peripheral
immune functions by PPAR-γ agonists may, therefore, represent an adjunctive target for neuroprotection (see text for references).
moreneurons[44,67,79–83](Figur e2).Insuchatoxicenvi-
ronment, it has been suggested that the elevated plasticity
of microglia and their interaction with adaptive immunity
cells (see later in this review) may lead them to assume
maladaptive functions, loosing their ability to self-modulate
themselves therefore perpetuating a neurotoxic phenotype
of activation, while failing to assume a neuroprotective
function [53, 76]( F i g u r e2). This view would prompt for
search of therapeutic strategies aimed at ﬁnely modulate
microglia activation. Optimal anti-inﬂammatory therapies
with neuroprotective target should be directed at selectively
suppress dangerous microglia phenotypes while stimulating
the neuroprotective ones, rather than generally suppress
microglia activation.
5.4. PPAR-γ Agonists and Reactive Gliosis in PD. Studies
in PD models in vivo have shown that PPAR-γ agonists-
mediated neuroprotection is consistently associated with
inhibition of microglial reactivity (Table 2). In MPTP-
exposed mice, the neuroprotective eﬀect of pioglitazone was
associated with the inhibition of microglial reactivity in the
SNc [8, 9]. Since pioglitazone exerts an inhibitory eﬀect
on monoamine oxidase B (MAO-B), therefore blocking
the conversion of MPTP to the toxic metabolite MPP+,
it has been claimed that this mechanism might account,
at least partly, for the neuroprotective activity displayed
by this drug upon MPTP intoxication [84]( T a b l e2).
However, in a diﬀerent PD model obtained by intrastriatal
infusion of lipopolysaccharide (LPS), neuroprotection by
pioglitazone was associated with inhibition of microglial
reactivity in the SNc and inhibition of LPS-induced increase
in mitochondrial proteins uncoupling protein 2 (UPS2)
and mitoNEET [42, 43]. Moreover, in a recent study con-
ducted by our group in a mouse model of progressive
PD induced by chronic delivery of MPTPp, rosiglitazone
prevented microglia activation [15]. Interestingly, while
microglial response was fully prevented by rosiglitazone inParkinson’s Disease 7
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.8 Parkinson’s Disease
the SNc, in line with a complete preservation of DA cell
bodies, in the striatum, a partial microglia inhibition was
associated with a partial rescue of DA content decline,
further interrelating the anti-inﬂammatory activity with the
neuroprotectiveeﬀect[15].Furthermore, when rosiglitazone
was introduced late in the chronic MPTP treatment, in
presence of an intense microgliosis and partial dopaminergic
degeneration, microglial response was partially inhibited
(unpublished observation). Importantly, in contrast to
pioglitazone, MPP+ levels were not altered by rosiglitazone
in mice chronically treated with MPTP, ruling out an eﬀect
on MPTP metabolism [15].
Several NSAID, as ibuprofen, fenoprofen, ﬂufenamidic
acid, indometacin, display a PPAR-γ agonistic activity [3, 4].
Noteworthy, these drugs have provided neuroprotection in
PD models, supporting a role for the anti-inﬂammatory
activity as mechanism of PPAR-γ-mediated neuroprotection
[85].
5.5. Modulation of Microglial Response as a Mechanism of
PPAR-γ-Mediated Neuroprotection. Although the preclinical
studies suggest the anti-inﬂammatory activity as a mech-
anism of neuroprotection by PPAR-γ agonists in PD, a
direct causal link has not been demonstrated. The in vivo
studies in PD models have reported the inhibition of iNOS
synthesis by pioglitazone, through an inhibition of NF-
kB activation, a main regulator of inﬂammatory genes
transcription, both in neurons and glial cells, oﬀering a
molecular mechanism for an anti-inﬂammatory-mediated
neuroprotection [9]. Accordingly, in an in vitro study con-
ducted in mesencephalic neuron-microglia mixed cultures,
pioglitazoneinhibitedLPS-inducedcyclooxygenase-2(COX-
2 )a c t i v i t y ,i N O Se x p r e s s i o n ,N Op r o d u c t i o na n dp 3 8M A P K
activity, achieving neuroprotection[86, 87].
Moreover, a direct evidence for PPAR-γ-mediated mod-
ulation of cytokines expression in experimental PD models
in vivo is lacking although a wealth of evidences supporting
this eﬀect as a mechanism of neuroprotection come from
in vitro studies. In LPS-stimulated microglial cells, natural
and synthetic PPAR-γ agonists were shown to inhibit the
production of pro-inﬂammatory and neurotoxic mediators
as TNF-α,I L - 1 β, IL-12, iNOS, as well as IFN-γ-induced
expression of major histocompatibility complex (MHC)
class II antigen [38, 88–91]. Interestingly, a recent study
suggested a role for the anti-inﬂammatory cytokine IL-
4i nt h eP P A R - γ-mediated inhibitory eﬀect, showing that
rosiglitazone attenuated LPS-induced increase of IL-1β and
MHC-II in microglia prepared from wild-type mice, but it
failed to exert any eﬀect in glia prepared from IL-4-deﬁcient
mice [92].
In addition to evidences gained from experimental PD, a
number of in vivo and in vitro studies in models of neurode-
generative and neuroinﬂammatory conditions other than
PD, have demonstrated a cytokine-modulatory activity of
PPAR-γ agonistsas mechanism ofneuroprotection.Inexper-
imental cerebral ischemia, diﬀerent TZDs, as pioglitazone,
troglitazone, and rosiglitazone were neuroprotective and
reduced protein and mRNA levels for the pro-inﬂammatory
cytokines IL-1β, IL-6, COX-2, and iNOS through an inhi-
bition of NF-kB signaling [93–95]. In an in vitro model
of Alzheimer disease, PPAR-γ agonists troglitazone and
ciglitazone suppressed the expression of the IL-6 and TNF-α
genes in Aβ-stimulated microglial cells, improving neuronal
survival [96].Interestingly, inthisstudyneuroprotectionwas
not achieved by direct application of PPAR-γ agonists to
the neurons, indicating that PPAR-γ agonists were directly
targeting microglial function [96].
All together, evidence in PD models and the knowledge
gained from diverse neurodegenerative conditions, suggest
that PPAR-γ agonists may achieve neuroprotection in PD
by mean of their anti-inﬂammatory activity and, speciﬁcally,
by ﬁnely modulating cytokines expression in microglia
through a main inhibitory eﬀect on NF-kB activity. The
speciﬁc inhibition of pro-inﬂammatory cytokines produc-
tion by microglia, together with a stimulatory eﬀect on
anti-inﬂammatory cytokines, suggest that PPAR-γ agonists
may direct activated microglia toward a less toxic or neu-
roprotective phenotype, while suppressing pro-inﬂammato-
ry/neurotoxic phenotypes (Figure 2).
BOX. The exact molecular mechanism of the PPAR-γ-
mediated anti-inﬂammatory activity remains controversial.
Upon activation by natural and synthetic agonists, PPAR-
γ heterodimerize with the retinoid X receptor (RXR) in
the cytoplasm, in this form translocating to the nucleus.
Herein, it binds to the PPAR-γ responsive elements (PPRE)
in the promoter region of PPAR target genes to modu-
late their expression [97–99]. In the absence of ligands,
the PPAR/RXR heterodimer is stabilized by the binding
of corepressors to suppress transcription, whereas ligand-
binding causes release of corepressors and recruitment of
co-activators, to activate transcription [100]. Besides this
transactivating activity, a ligand-dependent transcriptional
transrepression mechanism has been described, by which
activated PPAR-γ represses gene transcription in a DNA-
binding independent way through physically sequestering
activated transcriptional factors or their coactivators [101].
For instance, it was recently demonstrated that PPAR-γ can
inhibitNF-kBbyphysicalinteraction with subunitp65,orby
increasing inhibitory kappa B alpha (IkBα) expression [102].
In addition, a small, ubiquitin-like modiﬁer (SUMO)ylation
ofPPAR-γ hasbeendescribedasamechanismoftransrepres-
sion of NF-kB target pro-inﬂammatory genes, conferring to
PPAR-γ a ductile function of activator or repressor of NF-kB
target genes [103].
6.PPAR-γ and PeripheralInﬂammationinPD
6.1. Peripheral Inﬂammation in PD: Human. Postmortem
as well as in vivo studies in PD patients have suggested
that the pathological process leading to neurodegeneration
may involve cells of the peripheral immune system and
immune-mediated mechanisms. First report by McGeer
and colleagues demonstrated the presence of activated T
lymphocytes (CD8+) in the Parkinsonian SN, together with
elements of the complement pathway [104, 105]. Thereafter,Parkinson’s Disease 9
in an elegant study Orr and co-workers demonstrated
presence of IgG-immunopositive pigmented neurons in the
SN of both idiopathic and genetic forms of PD, associated
with an increase of activated microglia expressing high
aﬃnity activating IgG receptors (FcγRI) [106]. Microglia
contained pigment granules, supporting their involvement
in a phagocytic attack on IgG immunopositive pigmented
neurons [106]. These authors suggested that IgG binding
to DA neurons may result in their selective targeting and
subsequent destruction by activated microglia [106]. Lately,
Brochard and colleagues reported higher densities of CD8+
and CD4+ T lymphocytes in the brain of patients with PD
than in healthy brains [107].
Interestingly, abnormalities in peripheral immune func-
tions have been repeatedly described in the blood of
patients with PD, which suggest un imbalance toward
pro-inﬂammatory phenotypes for activated T lymphocytes.
Hisanaga and co-workers reported a signiﬁcantly greater
populationofcirculating CD3+CD4+ CD8+ Tlymphocytes
in blood of PD patients than in age-matched control
subjects [108]. In a study conducted in Parkinsonian versus
normal individuals, Baba and colleagues suggested a shift of
activated lymphocytes to a pro-inﬂammatory phenotype by
showing that patients with PD had signiﬁcantly decreased
CD4+: CD8+ T-cell ratio, fewer CD4+CD25+ T regulatory
cells (Treg), and increased ratios of IFN-γ-producing to
IL-4-producing T cells [109]. Accordingly, other studies
have reported higher levels of serum interleukins and pro-
inﬂammatory cytokines [59, 110, 111].
6.2. Peripheral Inﬂammation in PD: Experimental PD. Stud-
ies in experimental PD models support an involvement of
peripheral immunity in dopaminergic cell loss. He et al.
[112] demonstrated that injection of IgG from serum of
PD patients into the mouse SNc leads to microglial activa-
tion and subsequent dopaminergic degeneration, suggesting
that humoral immune mechanisms can trigger microglial-
mediated neuronal injury. Investigating a possible patholog-
ical relevance of lymphocytes inﬁltration in a experimental
MPTP model of PD, Brochard et al. [107] showed that
MPTP-damaged SNc speciﬁcally displayed presence of inﬁl-
trating T cells. Moreover, removal of CD4+ T cells in mutant
miceresultedinalowersensitivitytoMPTPandlowerdegree
of cell death in the SNc, strongly supporting a deleterious
contribution of peripheral lymphocytes to dopaminergic
degeneration within the SNc.
Moreover, a role for a dysregulated activation of T
lymphocytes in PD neuropathology has been recently sug-
gested in an in vivo PD model [113]. Thus, inoculation of
CD4+CD25+Tregcells,butnotCD4+CD25−eﬀectorTcells
(Teﬀ), reduced microglial reactivity and neurodegeneration
inMPTP-treated mice[113].Inaddition,amorerecentstudy
by the same authors strongly corroborates the relevance
of adaptive immunity cells subpopulations in directing
microglial response in PD [114]. Hence, the phenotype
undertaken by α-synuclein-activated microglia in culture,
depended upon the interaction with speciﬁc subpopulations
of activated T cells, with CD4+CD25+ Treg cells suppressing
α-synuclein-induced production of reactive oxygen species
and NF-kB activation. In contrast, CD4+CD25- eﬀector T
cells exacerbated microglial inﬂammation and neurotoxic
responses [76, 114].
Although it is not clear if abnormalities of the peripheral
immune system are secondary to changes in central immune
system,datafromPDcasesandexperimentalPDconsistently
report an inﬁltration of abnormally activated immune cells
across the blood brain barrier in PD. Consistent with a
Tc e l lf u n c t i o ni nd i r e c t i n gm i c r o g l i ap h e n o t y p e[ 56, 57],
abnormally activated T cells present in the damaged area
may inﬂuence the microenvironment by driving microglia
to acquire a neurotoxic phenotype to the detriment of less
toxic or neuroprotective states, actively contributing to the
pathological processes (Figure 2).
6.3. PPAR-Gamma Agonists and Peripheral Inﬂammation in
PD. PPAR-γ agonists exert profound and long-lasting anti-
inﬂammatory eﬀects in peripheral immune cells, mainly
directing their diﬀerentiation into alternate phenotypes [3,
10, 115]. In the light of the growing relevance that peripheral
immunity is gaining in PD pathology, this unique feature
of PPAR-γ agonists sues for further attention toward these
drugs as disease modifying strategy in PD. Albeit a direct
evidence for a contribution of this mechanism in PPAR-
γ-mediated neuroprotection in PD is currently missing,
a wealth of data indicate that modulation of peripheral
immunity is a main target for PPAR-γ-mediated protective
therapies in chronic inﬂammatory diseases, including neu-
roinﬂammatory conditionsasmultiplesclerosis,whereadys-
regulation of the peripheral immune system is instrumental
to the pathology.
PPAR-γ can aﬀect adaptive immune responses by mod-
ulating T cells diﬀerentiation and activity through mech-
anisms involving the suppression of pro-inﬂammatory
cytokines, as IL-2, which are known to play an important
role in directing T cells phenotype [116–118]. Noteworthy,
PPAR-γ-mediated suppression of a particular subset of
activated T cells, named T helper 17 (TH17), provides
beneﬁcial eﬀects to multiple sclerosis patients, asserting
PPAR-γ as a promising target for speciﬁc immunointer-
vention in autoimmune disorders [119]. TH17 has been
recently described, playing an important role in induc-
ing autoimmune tissue inﬂammations by the preferential
release of IL-17. IL-17 in turn promotes inﬂammation
through the production of pro-inﬂammatory cytokines
as IL-6, TNF-α,I L - 1 β, chemokines, and potentiate tissue
pathology by inducing the production of nitric oxide and
matrix metalloproteinases [120]. Evidencing the prominent
role played by PPAR-γ in the development of autoim-
munity, rosiglitazone can aﬀect CD4+ T cells function
by speciﬁcally suppressing their diﬀerentiation into TH17
[117, 119].
In addition to the anti-inﬂammatory function in adapt-
ive immune cells, PPAR-γ agonists suppress monocyte
elaboration of inﬂammatory cytokines and can prime
monocytes to diﬀerentiate into macrophages with an
anti-inﬂammatory phenotype [3, 121, 122]. In human10 Parkinson’s Disease
atherosclerotic lesions, and in cultured human monocytes,
PPAR-γ stimulation primed primary human monocytes to
be diﬀerentiated into the M2 form, the “alternative” anti-
inﬂammatory macrophage phenotype. This in turn aﬀected
M1 macrophages, which displayed a more pronounced
anti-inﬂammatory activity (the “classical” proatherogenic
phenotype) [122–124].
Tosummarize, peripheralPPAR-γ holdsthedoublefunc-
tion of selectively suppressing CD4+ activated T cells that
sustain tissue inﬂammation and of inducing macrophages
to diﬀerentiate into the anti-inﬂammatory M2 phenotype.
Therefore, this receptor contributes to keep in control the
inﬂammatory reactions in the tissue microenvironment and
to maintain immune homeostasis, either in the presence of
foreign pathogens/antigens or self-peptides insults. Within
a view that includes a role for humoral immunity in PD
pathogenesis, the restoration of disease-dysregulated periph-
eralimmunefunctions byPPAR-γ agonists,mayrepresentan
adjunctive target for neuroprotection in this neurodegenera-
tive disorder, prompting forfurther investigation in this ﬁeld
(Figure 2).
7.Conclusionsand FuturePerspectives
Currently,availabledrugsforPDtherapyonlyprovidesymp-
tomatic amelioration, while therapeutic strategies aimed at
stopping or modifying disease progression are still strongly
sought. Neuroinﬂammation plays a crucial role in the
neurodegenerative processes. Most recent research suggests
that both the central and peripheral immune systems are
dysregulated in PD, as suggested by a chronic prevalence
of a neurotoxic phenotype over anti-inﬂammatory states of
activation, reported foreithermicroglia orT cells. Therefore,
therapeutic strategies aimed at ﬁnely modulating microglial
activation,reinstating thephysiologicalshift toward lessneu-
rotoxic phenotypes, may represent a goal in neuroprotection.
This goal maybe achievedbyusing PPAR-γ agonists,because
their ability in modulating the expression of pro- and anti-
inﬂammatory cytokines at the transcriptional level in both
central and peripheral immune cells.
While the ability of PPAR-γ agonists to prevent neurode-
generation has been demonstrated in several experimental
models of PD, additional studies are needed to prove PPAR-
γ agonists eﬃcacy on disease progression. Moreover, in spite
of recent warning on the safety of these drugs in diabetes,
to our knowledge no safety records are available in non
diabetic individuals or PD patients. Therefore, translation to
the clinical trial is warranted to fully evaluate the therapeutic
potential in PD although safety could become a critical
issue.
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